Immunic, Inc. (IMUX) financial statements (2021 and earlier)

Company profile

Business Address AM KLOPFERSPITZ 19
MARTINSRIED, 82152
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments29303610131831
Cash and cash equivalents29303610131831
Receivables0 1    
Other current assets1      
Other undisclosed current assets2420112
Total current assets:32353910141933
Noncurrent Assets
Operating lease, right-of-use asset1   
Property, plant and equipment0000112
Intangible assets, net (including goodwill)333333    
Goodwill333333    
Other noncurrent assets0  0000
Other undisclosed noncurrent assets 00    
Total noncurrent assets:3433330112
TOTAL ASSETS:66687310152035
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6731268
Accounts payable2410011
Accrued liabilities3321257
Other liabilities1000000
Total current liabilities:7731368
Noncurrent Liabilities
Long-term debt and lease obligation1      
Operating lease, liability1   
Liabilities, other than long-term debt 00  00
Deferred revenue and credits0
Deferred rent credit     0 
Other liabilities 00    
Other undisclosed noncurrent liabilities    0  
Total noncurrent liabilities:100 000
Total liabilities:8731368
Stockholders' equity
Stockholders' equity attributable to parent5861699121426
Common stock0000000
Additional paid in capital120115114356350349349
Accumulated other comprehensive income (loss)(1)(2)(1)0000
Accumulated deficit(60)(52)(44)(347)(337)(335)(323)
Total stockholders' equity:5861699121426
TOTAL LIABILITIES AND EQUITY:66687310152035

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(8)(9)(15)(10)(3)(12)(13)
Operating loss:(8)(9)(15)(10)(3)(12)(13)
Nonoperating income0100000
Investment income, nonoperating0000000
Other nonoperating income (expense)010(0)000
Net loss available to common stockholders, diluted:(8)(8)(15)(9)(2)(12)(13)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(8)(8)(15)(9)(2)(12)(13)
Other comprehensive income (loss)0(1)0    
Other undisclosed comprehensive income    0  
Comprehensive loss:(7)(9)(14)(9)(2)(12)(13)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    (0) 0
Comprehensive loss, net of tax, attributable to parent:(7)(9)(14)(9)(2)(12)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: